ADCT Shariah Compliance
Screening Methodology: AAOIFI
As of July 2026, ADC Therapeutics SA is classified as not halal.
NOT HALAL
Report Source: 2026 1st Quarter Report
ADC Therapeutics SA. Stock Analysis ADCT
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. The company is headquartered in Epalinges, Vaud and currently employs 188 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
Read More ADC Therapeutics SA (ADCT) Chart
Key Statistics of ADC Therapeutics SA (ADCT)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$1.33Volume
957.73KP/E Ratio (TTM)
-52 Week Range
Market Cap
162.80MAvg. Volume
1.54MDividend Yield
-Financial Metrics & Statements of ADC Therapeutics SA (ADCT)
Super Investors Invested in ADC Therapeutics SA (ADCT)
FAQ's for ADC Therapeutics SA (ADCT)
- As of July 2026, ADC Therapeutics SA ADCT is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes ADC Therapeutics SA using these criteria to determine its compliance status.
- Muslim investors may consider investing in ADC Therapeutics SA if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of ADC Therapeutics SA by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of ADC Therapeutics SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of ADC Therapeutics SA on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
